Don't be surprised (or scared) to see coal tar as an ingredient in your shampoo bottle prescribed by a dermatologist. It is ...

Arcutis achieved earlier-than-expected profitability and continues expanding Zoryve's label for broader indications. Read why ...

Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and ...

Skin conditions with Parkinson’s disease are common and manageable. By paying attention to these symptoms, patients can ...

A dermatologist explains five common reasons that you might notice a bad smell behind your ears, plus the best way to clean ...

New clinical data demonstrate Zoryve's effectiveness in treating atopic dermatitis, reducing sleep disruptions and maintaining disease control with minimal adverse events across all ages.

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

AS the air gets crisp, and more people in the office sniffle, thoughts inevitably turn to the immune system. Everyone is ...

Parkinson's disease affects more than just movement. Skin issues like dryness, excessive sweating, and seborrheic dermatitis are common. These skin pr ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...

Roflumilast cream 0.05% is approved for children aged 2 to 5 with mild to moderate atopic dermatitis, offering a steroid-free option. The approval is based on three trials showing rapid clearance, ...

Findings showed 56.5% of patients receiving ruxolitinib cream 1.5% achieved IGA-TS compared with 10.8% of those receiving placebo. The Food and Drug Administration (FDA) has approved Opzelura ® ...